|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.94 SEK | -0.15% |
|
-4.56% | -33.83% |
| Jul. 08 | Hansa Biopharma Names New Chief Medical Officer | MT |
| Jul. 08 | Hansa Biopharma Appoints Richard Philipson as Chief Medical Officer, Effective 14 July, 2025 | CI |
| Capitalization | 2.2B 227M 195M 182M 169M 311M 19.5B 348M 833M 9.12B 851M 833M 33.77B | P/E ratio 2025 * |
-4.97x | P/E ratio 2026 * | -6.08x |
|---|---|---|---|---|---|
| Enterprise value | 3.24B 334M 287M 267M 249M 458M 28.69B 512M 1.23B 13.42B 1.25B 1.23B 49.68B | EV / Sales 2025 * |
10.9x | EV / Sales 2026 * | 5.98x |
| Free-Float |
69.23% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Hansa Biopharma AB
More recommendations
More press releases
| 1 day | +0.54% | ||
| 1 week | -4.19% | ||
| Current month | -0.61% | ||
| 1 month | +6.11% | ||
| 3 months | +21.00% | ||
| 6 months | -18.88% | ||
| Current year | -33.57% |
| 1 week | 25.72 |  | 27.38 |
| 1 month | 23.3 | | 29.14 |
| Current year | 19.58 | | 41 |
| 1 year | 19.58 | | 57.3 |
| 3 years | 19.58 | | 105.8 |
| 5 years | 19.58 | | 288.6 |
| 10 years | 18.8 | | 349.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 2025-04-23 | |
| Director of Finance/CFO | 65 | 2024-02-29 | |
| Chief Tech/Sci/R&D Officer | 61 | 2025-07-13 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 2018-05-28 | |
Eva Nilsagård
BRD | Director/Board Member | 61 | 2019-05-21 |
Mats Blom
BRD | Director/Board Member | 60 | 2019-05-21 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.54% | -4.19% | -46.60% | -53.54% | 227M | ||
| -0.35% | +0.04% | +9.45% | +0.04% | 49.68B | ||
| +6.96% | +10.32% | +82.53% | +52.24% | 31.95B | ||
| +0.90% | +1.77% | +3.36% | +8.76% | 28.45B | ||
| -1.53% | -4.13% | -30.20% | -28.03% | 27.28B | ||
| +0.53% | +1.51% | +27.39% | -22.72% | 12.54B | ||
| -2.64% | -3.96% | -57.29% | -31.05% | 11.57B | ||
| -0.08% | +3.91% | +27.52% | +104.79% | 10.58B | ||
| -1.72% | -0.84% | +10.36% | -4.71% | 10.28B | ||
| -3.34% | -4.48% | +52.70% | - | 9.68B | ||
| Average | -0.54% | +0.18% | +7.92% | +2.86% | 19.22B | |
| Weighted average by Cap. | -0.54% | +1.48% | +15.38% | +8.54% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 297M 30.6M 26.35M 24.52M 22.85M 41.99M 2.63B 46.97M 112M 1.23B 115M 112M 4.56B | 550M 56.62M 48.76M 45.37M 42.27M 77.7M 4.87B 86.9M 208M 2.28B 212M 208M 8.43B |
| Net income | -406M -41.81M -36.01M -33.51M -31.22M -57.38M -3.6B -64.17M -154M -1.68B -157M -154M -6.23B | -331M -34.05M -29.32M -27.28M -25.42M -46.72M -2.93B -52.26M -125M -1.37B -128M -125M -5.07B |
| Net Debt | 1.04B 107M 92.02M 85.62M 79.78M 147M 9.19B 164M 392M 4.3B 401M 392M 15.91B | 1.08B 112M 96.21M 89.52M 83.41M 153M 9.61B 171M 410M 4.49B 419M 410M 16.63B |
More financial data
* Estimated data
Employees
138
Calendar
Jul. 16
- Q2 2025 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-07-16 | 26.00 kr | +0.08% | 223,307 |
| 25-07-15 | 25.98 kr | -0.54% | 183,502 |
| 25-07-14 | 26.12 kr | -0.99% | 203,962 |
| 25-07-11 | 26.38 kr | -2.80% | 232,659 |
| 25-07-10 | 27.14 kr | -0.15% | 235,251 |
Delayed Quote Nasdaq Stockholm, July 16, 2025 at 04:13 am EDT
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
25.98SEK
Average target price
80.50SEK
Spread / Average Target
+209.85%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HNSA Stock
Select your edition
All financial news and data tailored to specific country editions
